CEVI CellaVision AB (publ)
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About CellaVision (STO: CEVI)
›
CellaVision (STO: CEVI) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 252 employees.
The shares were at 204.00 SEK on 19 November 2026, up 29.8% over 52 weeks. Its 52-week range is 117.60 SEK to 207.00 SEK: the price is 1.4% below the high and 73.5% above the low.
At a market capitalisation of 4.87B SEK, it trades at 35.4 times trailing earnings and 24.8 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 38% for CEVI. It pays a dividend yielding 1.35% (it pays out 48% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
CellaVision reports return on equity of 17.2%, an operating margin of 23.0% and revenue up 13.6% year over year.
It holds more cash than debt, a net cash position of 168.72M SEK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock; their mean price target of 198.33 SEK is 2.8% below the current price. The next earnings report is expected on 3 February 2027.